ATC Group: L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AK in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AK

Group L04AK contents

Code Title
L04AK01 Leflunomide
L04AK02

Active ingredients in L04AK

Active Ingredient Description
Leflunomide

Leflunomide is a disease-modifying anti-rheumatic agent with antiproliferative properties. A771726, the active metabolite of leflunomide, inhibits the human enzyme dihydroorotate dehydrogenase (DHODH) and exhibits antiproliferative activity.

Teriflunomide

Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), which functionally connects with the respiratory chain. As a consequence of the inhibition, teriflunomide generally reduces the proliferation of rapidly dividing cells that depend on de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes.

Related product monographs

Title Information Source Document Type  
ARAVA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
AUBAGIO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC